I could open it and just say we understand, and our members clearly understand, the difficulties just in speaking about biotechnology towards trade with the EU on biotech issues. It's difficult. Our expectations were extremely modest. There is a working group and there is the science-based regulation, one that we're particularly fond of, as you know. We'll hold onto that as a victory. Would we have liked more? Absolutely, in any trade negotiation you would like more.
But in recognizing just how challenging those issues are in dealing with the European Union, we'll grab that and we'll hold onto that, and we'll see if we can build on that success. It's baby steps when it comes to these issues.